Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Novo Nordisk current and future product portfolio covers the type 2 diabetes treatment flow¹ Overview of current and future products in Novo Nordisk's diabetes portfolio When basal insulin is not enough When metformin is not enough When it's time for insulin Once-daily optimisation Mealtime insulin control Slide 60 Second generation analogues oral semaglutide semaglutide TRESIBA Xultophy RYZODEG Faster acting insulin aspart or First generation analogues VICTOZAⓇ LevemirⓇ Novo Mix® Novo Rapid or Human insulin Insulatard® Mixtard® 30 ActrapidⓇ 1 Pending clinical development programmes and regulatory processes for semaglutide and faster-acting insulin aspart changing diabetes® novo nordisk

View entire presentation